Vanda Pharmaceuticals Inc. (VNDA) Form 8-K — Nov 20, 2026
Vanda Pharmaceuticals settled its patent infringement litigation against MSN Pharmaceuticals over HETLIOZ LQ (tasimelteon suspension), dismissing the Delaware District Court case and granting MSN a non-exclusive, royalty-free license to market its generic in the U.S. The license takes effect in the first quarter of 2040, giving Vanda roughly 13 more years of exclusivity, though MSN can enter earlier if the licensed patents expire or are invalidated, an authorized or licensed generic launches, or unlicensed third-party generics launch unchallenged. MSN gains 180-day pre-launch manufacturing rights and limited pre-launch commercial discussions.
Key figures
- License effective date
- first quarter of 2040
- Pricing contracting lead days
- 14
- Customer discussions lead days
- 30
- Pre launch manufacturing lead time days
- 180
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.